134 related articles for article (PubMed ID: 18600296)
1. False I50V resistance readings of HIV isolates: co-amplification of NASBA HIV-1 RNA QT internal calibrators and HIV-1 patient isolates may lead to a false I50V mutation resistance reading in genotypic tests.
Waléria-Aleixo A; Greco DB; Brindeiro R; Tanuri A
Arch Virol; 2008; 153(8):1489-94. PubMed ID: 18600296
[TBL] [Abstract][Full Text] [Related]
2. Genotypic resistance analysis of the virological response to fosamprenavir-ritonavir in protease inhibitor-experienced patients in CONTEXT and TRIAD clinical trials.
Marcelin AG; Flandre P; Molina JM; Katlama C; Yeni P; Raffi F; Antoun Z; Ait-Khaled M; Calvez V
Antimicrob Agents Chemother; 2008 Dec; 52(12):4251-7. PubMed ID: 18852278
[TBL] [Abstract][Full Text] [Related]
3. Evolution of the HIV-1 protease region in heavily pretreated HIV-1 infected patients receiving Atazanavir.
Vergani B; Cicero ML; Vigano' O; Sirianni F; Ferramosca S; Vitiello P; Di Vincenzo P; Pia De Pasquale M; Galli M; Rusconi S
J Clin Virol; 2008 Feb; 41(2):154-9. PubMed ID: 18024202
[TBL] [Abstract][Full Text] [Related]
4. HIV protease mutations associated with amprenavir resistance during salvage therapy: importance of I54M.
Murphy MD; Marousek GI; Chou S
J Clin Virol; 2004 May; 30(1):62-7. PubMed ID: 15072756
[TBL] [Abstract][Full Text] [Related]
5. Performance of drug-resistance genotypic assays among HIV-1 infected patients with predominantly CRF02_AG strains of HIV-1 in Abidjan, Cote d'Ivoire.
Bilé EC; Adjé-Touré C; Borget MY; Kalou M; Diomande F; Chorba T; Nkengasong JN
J Clin Virol; 2005 Jan; 32(1):60-6. PubMed ID: 15572008
[TBL] [Abstract][Full Text] [Related]
6. Amprenavir resistance imparted by the I50V mutation in HIV-1 protease can be suppressed by the N88S mutation.
Lam E; Parkin NT
Clin Infect Dis; 2003 Nov; 37(9):1273-4. PubMed ID: 14557976
[No Abstract] [Full Text] [Related]
7. Primary drug resistance in antiretroviral-naïve injection drug users.
Tossonian HK; Raffa JD; Grebely J; Viljoen M; Mead A; Khara M; McLean M; Krishnamurthy A; DeVlaming S; Conway B
Int J Infect Dis; 2009 Sep; 13(5):577-83. PubMed ID: 19111493
[TBL] [Abstract][Full Text] [Related]
8. Clinically validated mutation scores for HIV-1 resistance to fosamprenavir/ritonavir.
Masquelier B; Assoumou KL; Descamps D; Bocket L; Cottalorda J; Ruffault A; Marcelin AG; Morand-Joubert L; Tamalet C; Charpentier C; Peytavin G; Antoun Z; Brun-Vézinet F; Costagliola D;
J Antimicrob Chemother; 2008 Jun; 61(6):1362-8. PubMed ID: 18390885
[TBL] [Abstract][Full Text] [Related]
9. A contribution to the drug resistance mechanism of darunavir, amprenavir, indinavir, and saquinavir complexes with HIV-1 protease due to flap mutation I50V: a systematic MM-PBSA and thermodynamic integration study.
Leonis G; Steinbrecher T; Papadopoulos MG
J Chem Inf Model; 2013 Aug; 53(8):2141-53. PubMed ID: 23834142
[TBL] [Abstract][Full Text] [Related]
10. Genotypic and phenotypic evolution of HIV type-1 protease during in vitro sequential or concomitant combination of atazanavir and amprenavir.
Cunyat F; Ruiz L; Marfil S; Puig T; Bofill M; Blanco J; Clotet B; Cabrera C
Antivir Ther; 2010; 15(3):431-6. PubMed ID: 20516562
[TBL] [Abstract][Full Text] [Related]
11. Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens.
Colonno R; Rose R; McLaren C; Thiry A; Parkin N; Friborg J
J Infect Dis; 2004 May; 189(10):1802-10. PubMed ID: 15122516
[TBL] [Abstract][Full Text] [Related]
12. Impact of HIV-1 protease mutations A71V/T and T74S on M89I/V-mediated protease inhibitor resistance in subtype G isolates.
Gonzalez LM; Santos AF; Abecasis AB; Van Laethem K; Soares EA; Deforche K; Tanuri A; Camacho R; Vandamme AM; Soares MA
J Antimicrob Chemother; 2008 Jun; 61(6):1201-4. PubMed ID: 18356151
[TBL] [Abstract][Full Text] [Related]
13. Evolution and predictors of HIV type-1 drug resistance in patients failing combination antiretroviral therapy in Italy.
Di Giambenedetto S; Zazzi M; Corsi P; Gonnelli A; Di Pietro M; Giacometti A; Almi P; Trezzi M; Boeri E; Gianotti N; Menzo S; Del Gobbo R; Francisci D; Nerli A; Galli L; De Luca A;
Antivir Ther; 2009; 14(3):359-69. PubMed ID: 19474470
[TBL] [Abstract][Full Text] [Related]
14. Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replication.
Mo H; Parkin N; Stewart KD; Lu L; Dekhtyar T; Kempf DJ; Molla A
Antimicrob Agents Chemother; 2007 Feb; 51(2):732-5. PubMed ID: 17101675
[TBL] [Abstract][Full Text] [Related]
15. Human immunodeficiency virus type 1 hypersusceptibility to amprenavir in vitro can be associated with virus load response to treatment in vivo.
Zachary KC; Hanna GJ; D'Aquila RT
Clin Infect Dis; 2001 Dec; 33(12):2075-7. PubMed ID: 11700580
[TBL] [Abstract][Full Text] [Related]
16. HIV contamination of commercial PCR enzymes raises the importance of quality control of low-cost in-house genotypic HIV drug resistance tests.
Monleau M; Plantier JC; Peeters M
Antivir Ther; 2010; 15(1):121-6. PubMed ID: 20167998
[TBL] [Abstract][Full Text] [Related]
17. Primary genotypic resistance of HIV-1 to the maturation inhibitor PA-457 in protease inhibitor-experienced patients.
Malet I; Wirden M; Derache A; Simon A; Katlama C; Calvez V; Marcelin AG
AIDS; 2007 Apr; 21(7):871-3. PubMed ID: 17415044
[TBL] [Abstract][Full Text] [Related]
18. Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro.
Maguire MF; Guinea R; Griffin P; Macmanus S; Elston RC; Wolfram J; Richards N; Hanlon MH; Porter DJ; Wrin T; Parkin N; Tisdale M; Furfine E; Petropoulos C; Snowden BW; Kleim JP
J Virol; 2002 Aug; 76(15):7398-406. PubMed ID: 12097552
[TBL] [Abstract][Full Text] [Related]
19. Amino acid insertions at position 35 of HIV-1 protease interfere with virus replication without modifying antiviral drug susceptibility.
Paolucci S; Baldanti F; Dossena L; Gerna G
Antiviral Res; 2006 Mar; 69(3):181-5. PubMed ID: 16460817
[TBL] [Abstract][Full Text] [Related]
20. Development and optimization of an internally controlled dried blood spot assay for surveillance of human immunodeficiency virus type-1 drug resistance.
Buckton AJ; Bissett SL; Myers RE; Beddows S; Edwards S; Cane PA; Pillay D
J Antimicrob Chemother; 2008 Dec; 62(6):1191-8. PubMed ID: 18927229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]